Also found in: Dictionary, Wikipedia.
Related to solifenacin: Solifenacin succinate
Pregnancy Category: C
ClassificationTherapeutic: urinary tract antispasmodics
Overactive bladder with symptoms (urge incontinence, urgency, frequency).
Acts as a muscarinic (cholinergic) receptor antagonist; antagonizes bladder smooth muscle contraction.
Decreased symptoms of overactive bladder.
Absorption: Well absorbed (90%).
Protein Binding: 98%.
Metabolism and Excretion: Extensively metabolized by the CYP3A4 enzyme system. 69% excreted in urine as metabolites, 22% in feces.
Half-life: 45–68 hr.
|Oral||unknown||3–8 hr||24 hr|
Contraindicated in: Hypersensitivity;Urinary retention;Gastric retention;Uncontrolled angle-closure glaucoma;Severe hepatic impairment; Lactation: Lactation.
Use Cautiously in: Concurrent use of CYP3A4 inhibitors (use lower dose/clinical monitoring may be necessary);Moderate hepatic impairment (lower dose recommended);Renal impairment (dose should not exceed 5 mg/day if CCr <30 mL/min);Bladder outflow obstruction;GI obstructive disorders, severe constipation, or ulcerative colitis;Myasthenia gravis;Angle-closure glaucoma; Obstetric: Use only if maternal benefit outweighs fetal risk; Pediatric: Safety not established.
Adverse Reactions/Side Effects
Central nervous system
Ear, Eye, Nose, Throat
- blurred vision
- constipation (most frequent)
- dry mouth (most frequent)
- muscle weakness
- angioedema (life-threatening)
Drug-Drug interactionDrugs that induce or inhibit the CYP3A4 enzyme system may significantly alter levels; ketoconazole ↑ levels and risk of toxicity (do not exceed 5 mg/day).
Oral (Adults) 5 mg once daily, may be ↑ to 10 mg once daily; Concurrent use of ketoconazole or other potent CYP3A4 inhibitors—Dose should not exceed 5 mg/day.
Renal Impairment(Adults) CCr <30 mL/min—Dose should not exceed 5 mg/day.
Hepatic Impairment(Adults) Moderate hepatic impairment—Dose should not exceed 5 mg/day.
Tablets: 5 mg, 10 mg Cost: All strengths $703.66 / 90
- Monitor voiding pattern and assess symptoms of overactive bladder (urinary urgency, urinary incontinence, urinary frequency) to and periodically during therapy.
Potential Nursing DiagnosesImpaired urinary elimination (Indications)
- Do not confuse Vesicare (solifenacin) with Vesanoid (oral tretinoin).
- Oral: Administer once daily without regard to food. Tablets must be swallowed whole; do not break, crush, or chew.
- Instruct patient to take solifenacin as directed. Advise patient to read the Patient Information before starting therapy and with each prescription refill. If a dose is missed, skip dose and take next day; do not take 2 doses in same day.
- Do not share solifenacin with others; may be dangerous.
- May cause dizziness and blurred vision. Caution patient to avoid driving and other activities that require alertness until response to medication is known.
- Advise patient to notify health care professional immediately if hives; rash; swelling or lips, face, tongue, or throat; trouble breathing occurs.
- Inform patient of potential anticholinergic side effects (constipation, urinary retention, blurred vision, heat prostration in a hot environment).
- Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
- Decrease in symptoms of overactive bladder (urge urinary incontinence, urgency, frequency).
Drug Guide, © 2015 Farlex and Partners